 Laboratory Equipment |
Mutated Antibodies Key to Treating Dengue Virus
Laboratory Equipment In a paper published in the Proceedings of the National Academy of Sciences, the researchers, from MIT’s Koch Institute of Integrative Cancer Research, present a novel approach to developing a dengue therapy using mutated antibodies. According to a … |
OncLiveNumerous Drug Classes Studied for Use in Follicular LymphomaOncLiveOfatumumab, a humanized monoclonal anti-CD20 antibody approved under the trade name Arzerra for use in chronic lymphocytic leukemia (CLL), has shown some promise as a single agen…
New Research on HIV Antibodies: Is a Vaccine in Sight?The Disease DailyWhen a person is infected by any pathogen, the immune system starts producing antibodies, or proteins that identify and neutralize pathogens. For the first few weeks after infection…
|
Innovator’s New Book Unveils Tips and Tricks To Avoid Corporate Antibodies …
PR Web (press release) Innovator’s New Book Unveils Tips and Tricks To Avoid Corporate Antibodies, Organ Rejection, and Death by PowerPoint. Serial intrapreneur and author, Dave Ulmer, takes a provocative look at how large corporations inadvertently and repeatedly kill off … |
|
MIT researchers present novel approach to develop dengue therapy using …
News-Medical.net In a paper published today in the Proceedings of the National Academy of Sciences, the researchers, from MIT’s Koch Institute of Integrative Cancer Research, present a novel approach to developing a dengue therapy using mutated antibodies. According to … |
|
Research advances therapy to protect against dengue virus
MIT News In a paper published today in the Proceedings of the National Academy of Sciences, the researchers, from MIT’s Koch Institute of Integrative Cancer Research, present a novel approach to developing a dengue therapy using mutated antibodies. According to … |
|
Surveyed U.S. Neurologists Would Prescribe Biogen Idec’s Tecfidera to 20 …
Sacramento Bee Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents—Lemtrada, ocrelizumab and AbbVie/Biogen Idec’s daclizumab—have advantages in reducing ARR over Teva’s Copaxone, the … |
 MarketWatch (press release) |
Surveyed US Neurologists Would Prescribe Biogen Idec’s Tecfidera to 20 …
MarketWatch (press release) Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents–Lemtrada, ocrelizumab and AbbVie/Biogen Idec’s daclizumab–have advantages in reducing ARR over Teva’s Copaxone, the … |
Oiling up immunityWellBeingWhen a foreign substance enters your body B-cells respond to the foreign proteins by producing specific antibodies. Antibodies are complex proteins that are released into the blood and carried to the site of infection. B-cell…
|
Surveyed U.S. Neurologists Would Prescribe Biogen Idec’s Tecfidera to 20 …
PR Newswire (press release) Clinical data and the opinions of thought leaders interviewed by Decision Resources indicate that other emerging agents—Lemtrada, ocrelizumab and AbbVie/Biogen Idec’s daclizumab—have advantages in reducing ARR over Teva’s Copaxone, the … |